Gain Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Gain Therapeutics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage allosteric biotech with differentiated discovery platform and Phase 1b data, but unprofitable with declining cash runway demanding near-term catalysts. Rexaceract demonstrated positive Phase 1 results in healthy volunteers and Parkinson's disease patients showing biomarker and clinical evidence of activity with favorable safety. However, cash declined to $13.1M as.
What is Gain Therapeutics, Inc.'s industry? Gain Therapeutics, Inc. (gaintherapeutics.com) operates in Neurology Drugs. AskCyborg classifies Gain Therapeutics, Inc. under Neurology Drugs in its company registry.
Gain Therapeutics is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. With its Magellan drug discovery platform, the company integrates AI, physics-...
Cyborg Score thesis
Early-stage allosteric biotech with differentiated discovery platform and Phase 1b data, but unprofitable with declining cash...
Read the full analyst-debate transcript →Get the Latest Gain Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGain Therapeutics, Inc. Overview
Pro stress-test →Gain Therapeutics is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. With its Magellan drug discovery platform, the company integrates AI, physics-based methods, and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 5 trillion compounds in less than 3 months. Its lead drug candidate, GT-02287 (now called rexaceract), is in Phase 1b evaluation for Parkinson's disease with potential in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease.
Strategic Profile
Pro stress-test →The company's proprietary SEE-Tx target identification platform identifies and optimizes previously untargeted allosteric binding sites, enabling development of new treatments for disorders characterized by protein misfolding. Gain targets a capital-efficient drug discovery approach using computational methods rather than traditional screening, positioning it to advance multiple pipeline programs across CNS, lysosomal, metabolic, and oncology indications.
Competitive Landscape
Pro stress-test →Direct competitors in neurodegenerative/allosteric space include Polaryx Therapeutics, Capsida Biotherapeutics, Neurometa Therapeutics, Voyager Therapeutics, and Regenxbio. Gain differentiates through its computational Magellan platform targeting allosteric sites, but faces competition from larger biopharmaceutical firms also advancing Parkinson's therapeutics.
Industry Context
Gain Therapeutics, Inc. operates in Neurology Drugs.
Key facts
Founded: 2017 · Headquarters: Bethesda, Maryland, US · Market cap: $81.5M (as of July 2, 2026)